Biopharma

AI accelerates the search for new tuberculosis drug tar...

Tuberculosis is a serious global health threat that infected more than 10 millio...

Omega-3s can slow down aging process

Many people would like to delay or even stop the aging process. Previous clinica...

AI tool helps find life-saving medicine for rare disease

After combing through 4,000 existing medications, an artificial intelligence too...

Amgen obesity drug on hold; Regeneron sets first dividend

Elsewhere, cell therapy developer Turnstone Biologics announced a second round o...

Novo outlines new late-stage study of obesity drug Cagr...

CagriSema, which underperformed expectations in its first Phase 3 test, will be ...

Cullinan CEO talks autoimmune pivot, upcoming lupus rea...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to ...

Fierce Biotech Layoff Tracker 2025: Viracta shuts down;...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Boston Scientific clocks over $1B in Farapulse revenue ...

That includes treating more than 200,000 patients with the irregular heartbeat k...

Glucotrack’s 3-year diabetes sensor implant clears init...

Glucotrack has cleared the first human clinical study of its long-term continuou...

X4 lays off 30% of staff, halts preclinical R&D to focu...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as...

AstraZeneca CEO defends 'fantastic' Alexion buyout in f...

AstraZeneca has ended development of its oral factor D inhibitor vemircopan, tri...

LinusBio to launch autism diagnostic aid that uses a si...

LinusBio aims to help physicians rule out the likelihood of autism developing in...

BD bids farewell to its diagnostic, bioscience division...

The “New BD,” as the company describes it, will continue on as a pure-play medte...

Kura and Kyowa hail phase 2 win for leukemia drug soon ...

Kura Oncology and Kyowa Kirin claim to have scored a phase 2 win for their oral ...

Eli Lilly's next R&D focus: Testing incretin meds in ne...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside ...

Chutes & Ladders—J&J vet jumps to Affinia

Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joi...

Acelyrin to be absorbed into Alumis in all-stock merger

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease speci...

After phase 3 miss, Relmada picks up midstage Tourette’...

After sharing plans to shutter last summer, Asarina Pharma has managed to sell o...

Bristol Myers backs out of Dupixent fight, axing allerg...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plan...

eGenesis announces 2nd pig kidney procedure success, as...

The procedure was performed January 25 by surgeons at the Mass General Transplan...

Illumina posts mixed earnings report while dealing with...

The DNA sequencing giant said it will continue to do business in China as long a...

New AI-discovered protein compounds kill bacteria and f...

Researchers have used artificial intelligence to identify 25 new protein compoun...

With Blenrep's revival, GSK dials up long-term sales go...

After re-adding Blenrep to its portfolio, GSK now expects sales to reach more th...

Avalere Health refocuses on ensuring access to care und...

Amar Urhekar has reset Avalere Health’s mission. Weeks after naming Urhekar as C...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.